FDA Denies Approval for Friedreich Ataxia Agent Vatiquinone, Citing More Efficacy Needed
Written by
Neurology Live
Published
0
comments
0
min
PTC Therapeutics faces FDA setback for vatiquinone, a potential Friedreich ataxia treatment, requiring further studies to demonstrate efficacy.